<DOC>
	<DOCNO>NCT00388362</DOCNO>
	<brief_summary>To study effectiveness immunosuppressive drug , sirolimus treatment chronic graft versus host disease combination prednisone .</brief_summary>
	<brief_title>Sirolimus Treatment Steroid-Refractory Steroid-Dependent Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description>The purpose trial study effectiveness immunosuppressive drug , sirolimus , treatment chronic graft versus host disease combination prednisone . Graft versus host disease ( GVHD ) common complication patient receive blood marrow transplantation relate unrelated donor . Chronic GVHD occur approximately 100 day transplantation result donor immune system recognize patient 's tissue foreign create harmful effect patient ' ; organ . We hope use sirolimus decrease significant disabling effect death cause chronic GVHD .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologicallyconfirmed active chronic GVHD &gt; 100 day follow allogeneic bone marrow/peripheral blood/umbilical cord blood transplantation fail prior therapy . In event histological confirmation pose undue risk , clinical evaluation sufficient . Women must negative pregnancy test sirolimus administration woman childbearing potential agree use medically acceptable contraceptive throughout treatment period 3 month discontinuation sirolimus . Any woman become pregnant treatment period must discontinue use sirolimus . Absolute neutrophil count ( ANC ) &gt; 1000/mm^3 , unless receive GCSF maintain neutrophil count &gt; 500/mm^3 Discontinuation cyclosporine FK506 time initiate sirolimus cyclosporine trough level &lt; 100 mg/dl FK506 level &lt; 5 mg/dl Karnofsky performance score &gt; = 50 prestudy screen Written , sign , date informed consent Uncontrolled systemic infection Unstable disease state ( i.e. , hepatic failure , ventilatorydependent respiratory failure , etc . ) Serum creatinine &gt; = 3.0 mg/dL , platelet count &lt; = 50,000/mm^3 History Posttransplant microangiopathic hemolytic anemia Uncontrolled hyperlipidemia Use investigational drug within 4 week entry study Use methotrexate antibody therapy within 24 hour sirolimus administration Inability tolerate oral therapy reason Evidence infiltrate , cavitation , consolidation chest xray prestudy screen Known hypersensitivity macrolide antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>GVHD</keyword>
</DOC>